Showing results (41-50 of 47) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 47 results.
Journal of Clinical Medicine|January 11, 2025
Tildrakizumab and Quality of Life: Deep Dive into the Impact of Psoriasis and Treatment on Different Domains-Should Psychosocial Life Impairment Be Considered a Comorbidity?Gaetano Licata, Eugenia Veronica Di Brizzi, Franco Castelli, et al.
Dermatology Practical & Conceptual|March 21, 2025
Risankizumab Versus Secukinumab: A Real-World Efficacy and Cost per Responder Comparison in Patients With Psoriasis in ItalyFederico Pirro, Giacomo Caldarola, Nicoletta Bernardini, et al.
Dermatology Practical & Conceptual|April 14, 2025
Evaluating the Efficacy of Bimekizumab across the Different Sensitive Areas in Moderate-to-Severe Psoriasis: A 52-week Italian Multicenter Real-Life Lazio ExperienceAnnunziata Dattola, Nicoletta Bernardini, Elena Campione, et al.
The Journal of Dermatological Treatment|October 27, 2024
Effectiveness of tildrakizumab 200 mg: an Italian multicenter studyAnnunziata Dattola, Nicoletta Bernardini, Francesca Svara, et al.
Clinics and Practice|March 27, 2026
Psoriasis in Difficult-to-Treat Areas: A Multicentre, Real-World Retrospective Study Analyzing the Impact of Non-Invasive Imaging Techniques (Dermoscopy, Reflectance Confocal Microscopy and Optical Coherence Tomography) to Monitor the Effectiveness of Risankizumab in the Treatment of Plaque Psoriasis of the LegsAnnunziata Dattola, Raimondo Rossi, Giuseppe Rizzuto, et al.
Frontiers in Big Data|January 24, 2022
Preparing Distributed Computing Operations for the HL-LHC Era With Operational IntelligenceAlessandro Di Girolamo, Federica Legger, Panos Paparrigopoulos, et al.
The Journal of Dermatological Treatment|September 24, 2025
Psoriasis severity, comorbidity burden, and biologic therapy: a multicenter observational study using the Charlson Comorbidity IndexNicoletta Bernardini, Annunziata Dattola, Giuseppe Paolo Antonio Gemma, et al.
Pageof 5